Access Biotechnology
New York, New York, United StatesFounded 2016
Access Biotechnology is the life science investment arm of Access Industries, focusing on private and public biopharma companies developing transformative therapies for conditions with high unmet needs. It invests across a broad range of stages, from discovery-stage technology platforms to late-stage clinical programs.
56% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 3 prior). Their most common stage is series-b (41% of deals). Average disclosed round size is $142.9M (across 32 rounds with reported amounts).
Portfolio
31
Fund Size
—
Top Stage
Series B
Last 12 Mo
3
Team
DB
Dan Becker
Managing Director
LR
Liam Ratcliffe
Managing Director
AS
Aliyah Silver
Associate
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
34 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Recludix Pharma | Unknown | — | Jan 2026 |
| OOnKure Therapeutics, Inc. | Series C | $150M | Jan 2026 |
| HHemab | Series C | $157M | Oct 2025 |
 Surrozen | Series D | $175M | Mar 2025 |
 Latigo Biotherapeutics | Series B | $150M | Mar 2025 |
 Draig Therapeutics | Series A | $140M | Jan 2025 |
 Halda | Series B | $126M | Aug 2024 |
| HHalda Therapeutics | Series B | $126M | Jan 2024 |
 Mariana Oncology | Series B | $175M | Sep 2023 |
| UUpstream Bio, Inc. | Series B | $200M | Jun 2023 |
 Hemab Therapeutics | Series B | $135M | Feb 2023 |
| HHemab Therapeutics Holdings | Series B | $135M | Feb 2023 |
| AAcelyrin, Inc | Series C | $300M | Sep 2022 |
| AAcelyrin | Series C | $300M | Sep 2022 |
 Upstream Bio | Series A | $200M | Jun 2022 |
 Nimbus | Unknown | $125M | Jan 2022 |
| CCurie Therapeutics Inc. | Series A | $75M | Dec 2021 |
 Disc Medicine | Series B | $90M | Sep 2021 |
 Climb Bio | Series B | $60M | May 2021 |
| DDTx Pharma | Series B | $100M | Mar 2021 |
 Verona Pharma | Unknown | $200M | Jan 2020 |
| VVerona Pharma PLC | Unknown | $200M | Jan 2020 |
 Trefoil Therapeutics | Series A | $28M | Jul 2019 |
 Oruka Therapeutics | Growth | $275M | — |
 Santa Ana Bio | Series B | $125M | — |
Page 1 of 2
Top Co-Investors
RA Capital Management17 shared
Deep Track Capital10 shared
OrbiMed9 shared
Samsara BioCapital8 shared
Atlas Venture7 shared
Rock Springs Capital6 shared
Westlake Village BioPartners5 shared
Alexandria Venture Investments5 shared
Vivo Capital5 shared
Surveyor Capital5 shared
Sanofi Ventures4 shared
Foresite Capital4 shared
Novo Holdings A/S4 shared
Maj Invest4 shared
HealthCap4 shared
The Invus Group, LLC4 shared
Perceptive Advisors4 shared
Canaan Partners4 shared
Bain Capital Life Sciences4 shared
Decheng Capital4 shared
Last updated: 8 September 2026